nodes	percent_of_prediction	percent_of_DWPC	metapath
Flunisolide—Hoarseness—Sorafenib—liver cancer	0.033	0.0445	CcSEcCtD
Flunisolide—Oropharyngeal discomfort—Sorafenib—liver cancer	0.0199	0.0269	CcSEcCtD
Flunisolide—Rhinorrhoea—Sorafenib—liver cancer	0.0179	0.0242	CcSEcCtD
Flunisolide—Dysphonia—Sorafenib—liver cancer	0.0176	0.0238	CcSEcCtD
Flunisolide—Glossitis—Sorafenib—liver cancer	0.0157	0.0212	CcSEcCtD
Flunisolide—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.0137	0.0529	CbGpPWpGaD
Flunisolide—Eczema—Sorafenib—liver cancer	0.0117	0.0158	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TAT—liver cancer	0.00979	0.0377	CbGpPWpGaD
Flunisolide—Nasopharyngitis—Sorafenib—liver cancer	0.00941	0.0127	CcSEcCtD
Flunisolide—Abdominal discomfort—Sorafenib—liver cancer	0.00872	0.0118	CcSEcCtD
Flunisolide—Oral candidiasis—Epirubicin—liver cancer	0.00844	0.0114	CcSEcCtD
Flunisolide—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00824	0.0318	CbGpPWpGaD
Flunisolide—Pneumonia—Sorafenib—liver cancer	0.00816	0.011	CcSEcCtD
Flunisolide—Hypokinesia—Epirubicin—liver cancer	0.00794	0.0107	CcSEcCtD
Flunisolide—Stomatitis—Sorafenib—liver cancer	0.00791	0.0107	CcSEcCtD
Flunisolide—Oral candidiasis—Doxorubicin—liver cancer	0.00781	0.0105	CcSEcCtD
Flunisolide—Epistaxis—Sorafenib—liver cancer	0.00765	0.0103	CcSEcCtD
Flunisolide—Laryngitis—Epirubicin—liver cancer	0.00744	0.01	CcSEcCtD
Flunisolide—Hypokinesia—Doxorubicin—liver cancer	0.00735	0.00992	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptors—NR1I3—liver cancer	0.00709	0.0274	CbGpPWpGaD
Flunisolide—Erythema multiforme—Sorafenib—liver cancer	0.00689	0.0093	CcSEcCtD
Flunisolide—Laryngitis—Doxorubicin—liver cancer	0.00688	0.00929	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—CPT1B—liver cancer	0.00665	0.0257	CbGpPWpGaD
Flunisolide—Stinging—Epirubicin—liver cancer	0.00662	0.00893	CcSEcCtD
Flunisolide—Ageusia—Epirubicin—liver cancer	0.00662	0.00893	CcSEcCtD
Flunisolide—Dysphonia—Epirubicin—liver cancer	0.00651	0.00879	CcSEcCtD
Flunisolide—Malnutrition—Sorafenib—liver cancer	0.00634	0.00856	CcSEcCtD
Flunisolide—Dysgeusia—Sorafenib—liver cancer	0.00621	0.00838	CcSEcCtD
Flunisolide—Ageusia—Doxorubicin—liver cancer	0.00612	0.00826	CcSEcCtD
Flunisolide—Stinging—Doxorubicin—liver cancer	0.00612	0.00826	CcSEcCtD
Flunisolide—Dysphonia—Doxorubicin—liver cancer	0.00603	0.00814	CcSEcCtD
Flunisolide—Cough increased—Epirubicin—liver cancer	0.00585	0.0079	CcSEcCtD
Flunisolide—Glossitis—Epirubicin—liver cancer	0.00582	0.00785	CcSEcCtD
Flunisolide—Lacrimation increased—Epirubicin—liver cancer	0.00582	0.00785	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—NR1H4—liver cancer	0.0057	0.022	CbGpPWpGaD
Flunisolide—Syncope—Sorafenib—liver cancer	0.00569	0.00768	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—NR1I3—liver cancer	0.0056	0.0216	CbGpPWpGaD
Flunisolide—Loss of consciousness—Sorafenib—liver cancer	0.00557	0.00752	CcSEcCtD
Flunisolide—Cough—Sorafenib—liver cancer	0.00553	0.00747	CcSEcCtD
Flunisolide—Hypertension—Sorafenib—liver cancer	0.00547	0.00739	CcSEcCtD
Flunisolide—Neck pain—Epirubicin—liver cancer	0.00542	0.00732	CcSEcCtD
Flunisolide—Cough increased—Doxorubicin—liver cancer	0.00542	0.00731	CcSEcCtD
Flunisolide—Myalgia—Sorafenib—liver cancer	0.0054	0.00729	CcSEcCtD
Flunisolide—Lacrimation increased—Doxorubicin—liver cancer	0.00538	0.00726	CcSEcCtD
Flunisolide—Glossitis—Doxorubicin—liver cancer	0.00538	0.00726	CcSEcCtD
Flunisolide—Vaginal inflammation—Epirubicin—liver cancer	0.00536	0.00724	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—liver cancer	0.00514	0.0198	CbGpPWpGaD
Flunisolide—Infection—Sorafenib—liver cancer	0.00514	0.00694	CcSEcCtD
Flunisolide—Candida infection—Epirubicin—liver cancer	0.00512	0.00691	CcSEcCtD
Flunisolide—Shock—Sorafenib—liver cancer	0.00509	0.00687	CcSEcCtD
Flunisolide—Vaginal infection—Epirubicin—liver cancer	0.00506	0.00683	CcSEcCtD
Flunisolide—Neck pain—Doxorubicin—liver cancer	0.00502	0.00678	CcSEcCtD
Flunisolide—Vaginal inflammation—Doxorubicin—liver cancer	0.00496	0.0067	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptors—HNF4A—liver cancer	0.00492	0.019	CbGpPWpGaD
Flunisolide—Candida infection—Doxorubicin—liver cancer	0.00473	0.00639	CcSEcCtD
Flunisolide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00471	0.00636	CcSEcCtD
Flunisolide—Vaginal infection—Doxorubicin—liver cancer	0.00468	0.00632	CcSEcCtD
Flunisolide—Dyspnoea—Sorafenib—liver cancer	0.00461	0.00623	CcSEcCtD
Flunisolide—Lymphadenopathy—Epirubicin—liver cancer	0.00456	0.00616	CcSEcCtD
Flunisolide—Dyspepsia—Sorafenib—liver cancer	0.00455	0.00615	CcSEcCtD
Flunisolide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00454	0.0175	CbGpPWpGaD
Flunisolide—Decreased appetite—Sorafenib—liver cancer	0.0045	0.00607	CcSEcCtD
Flunisolide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00447	0.0172	CbGpPWpGaD
Flunisolide—Fatigue—Sorafenib—liver cancer	0.00446	0.00602	CcSEcCtD
Flunisolide—Pain—Sorafenib—liver cancer	0.00442	0.00597	CcSEcCtD
Flunisolide—Constipation—Sorafenib—liver cancer	0.00442	0.00597	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—HNF4A—liver cancer	0.00437	0.0169	CbGpPWpGaD
Flunisolide—Eczema—Epirubicin—liver cancer	0.00433	0.00584	CcSEcCtD
Flunisolide—Gastrointestinal pain—Sorafenib—liver cancer	0.00423	0.00571	CcSEcCtD
Flunisolide—Lymphadenopathy—Doxorubicin—liver cancer	0.00422	0.0057	CcSEcCtD
Flunisolide—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00416	0.016	CbGpPWpGaD
Flunisolide—Increased appetite—Epirubicin—liver cancer	0.00414	0.00559	CcSEcCtD
Flunisolide—Urticaria—Sorafenib—liver cancer	0.00411	0.00555	CcSEcCtD
Flunisolide—Body temperature increased—Sorafenib—liver cancer	0.00409	0.00552	CcSEcCtD
Flunisolide—Abdominal pain—Sorafenib—liver cancer	0.00409	0.00552	CcSEcCtD
Flunisolide—Eczema—Doxorubicin—liver cancer	0.00401	0.00541	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—HNF4A—liver cancer	0.00388	0.015	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—NR1I3—liver cancer	0.00383	0.0148	CbGpPWpGaD
Flunisolide—Increased appetite—Doxorubicin—liver cancer	0.00383	0.00517	CcSEcCtD
Flunisolide—Migraine—Epirubicin—liver cancer	0.00383	0.00517	CcSEcCtD
Flunisolide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00382	0.0147	CbGpPWpGaD
Flunisolide—Hypersensitivity—Sorafenib—liver cancer	0.00381	0.00515	CcSEcCtD
Flunisolide—Asthenia—Sorafenib—liver cancer	0.00371	0.00501	CcSEcCtD
Flunisolide—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00367	0.0142	CbGpPWpGaD
Flunisolide—Pruritus—Sorafenib—liver cancer	0.00366	0.00494	CcSEcCtD
Flunisolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—liver cancer	0.00362	0.014	CbGpPWpGaD
Flunisolide—Migraine—Doxorubicin—liver cancer	0.00354	0.00478	CcSEcCtD
Flunisolide—Diarrhoea—Sorafenib—liver cancer	0.00354	0.00478	CcSEcCtD
Flunisolide—Nasopharyngitis—Epirubicin—liver cancer	0.00348	0.0047	CcSEcCtD
Flunisolide—Dizziness—Sorafenib—liver cancer	0.00342	0.00462	CcSEcCtD
Flunisolide—Abdominal distension—Epirubicin—liver cancer	0.00339	0.00457	CcSEcCtD
Flunisolide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—liver cancer	0.00331	0.0127	CbGpPWpGaD
Flunisolide—Vomiting—Sorafenib—liver cancer	0.00329	0.00444	CcSEcCtD
Flunisolide—Rash—Sorafenib—liver cancer	0.00326	0.0044	CcSEcCtD
Flunisolide—Dermatitis—Sorafenib—liver cancer	0.00326	0.0044	CcSEcCtD
Flunisolide—Headache—Sorafenib—liver cancer	0.00324	0.00438	CcSEcCtD
Flunisolide—Bronchitis—Epirubicin—liver cancer	0.00323	0.00437	CcSEcCtD
Flunisolide—Nasopharyngitis—Doxorubicin—liver cancer	0.00322	0.00435	CcSEcCtD
Flunisolide—NR3C1—Adipogenesis—SCD—liver cancer	0.0032	0.0123	CbGpPWpGaD
Flunisolide—Abdominal distension—Doxorubicin—liver cancer	0.00313	0.00423	CcSEcCtD
Flunisolide—Upper respiratory tract infection—Epirubicin—liver cancer	0.00313	0.00422	CcSEcCtD
Flunisolide—NR3C1—AP-1 transcription factor network—ATF3—liver cancer	0.00312	0.012	CbGpPWpGaD
Flunisolide—Nausea—Sorafenib—liver cancer	0.00307	0.00415	CcSEcCtD
Flunisolide—Weight increased—Epirubicin—liver cancer	0.00306	0.00413	CcSEcCtD
Flunisolide—Pneumonia—Epirubicin—liver cancer	0.00302	0.00407	CcSEcCtD
Flunisolide—Bronchitis—Doxorubicin—liver cancer	0.00299	0.00404	CcSEcCtD
Flunisolide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00296	0.0114	CbGpPWpGaD
Flunisolide—Stomatitis—Epirubicin—liver cancer	0.00292	0.00395	CcSEcCtD
Flunisolide—Conjunctivitis—Epirubicin—liver cancer	0.00291	0.00393	CcSEcCtD
Flunisolide—Urinary tract infection—Epirubicin—liver cancer	0.00291	0.00393	CcSEcCtD
Flunisolide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00289	0.0039	CcSEcCtD
Flunisolide—Sweating—Epirubicin—liver cancer	0.00287	0.00388	CcSEcCtD
Flunisolide—Weight increased—Doxorubicin—liver cancer	0.00283	0.00382	CcSEcCtD
Flunisolide—Epistaxis—Epirubicin—liver cancer	0.00283	0.00382	CcSEcCtD
Flunisolide—Sinusitis—Epirubicin—liver cancer	0.00281	0.0038	CcSEcCtD
Flunisolide—Pneumonia—Doxorubicin—liver cancer	0.00279	0.00377	CcSEcCtD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—liver cancer	0.00278	0.0107	CbGpPWpGaD
Flunisolide—Stomatitis—Doxorubicin—liver cancer	0.0027	0.00365	CcSEcCtD
Flunisolide—Rhinitis—Epirubicin—liver cancer	0.0027	0.00364	CcSEcCtD
Flunisolide—Urinary tract infection—Doxorubicin—liver cancer	0.0027	0.00364	CcSEcCtD
Flunisolide—Conjunctivitis—Doxorubicin—liver cancer	0.0027	0.00364	CcSEcCtD
Flunisolide—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00269	0.0104	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—HNF4A—liver cancer	0.00268	0.0103	CbGpPWpGaD
Flunisolide—Hypoaesthesia—Epirubicin—liver cancer	0.00268	0.00362	CcSEcCtD
Flunisolide—Pharyngitis—Epirubicin—liver cancer	0.00267	0.00361	CcSEcCtD
Flunisolide—Sweating—Doxorubicin—liver cancer	0.00266	0.00359	CcSEcCtD
Flunisolide—Oedema peripheral—Epirubicin—liver cancer	0.00265	0.00358	CcSEcCtD
Flunisolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PPARA—liver cancer	0.00264	0.0102	CbGpPWpGaD
Flunisolide—Epistaxis—Doxorubicin—liver cancer	0.00262	0.00353	CcSEcCtD
Flunisolide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00261	0.0101	CbGpPWpGaD
Flunisolide—Sinusitis—Doxorubicin—liver cancer	0.0026	0.00351	CcSEcCtD
Flunisolide—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.0026	0.01	CbGpPWpGaD
Flunisolide—NR3C1—Nuclear Receptors—PPARA—liver cancer	0.00258	0.00996	CbGpPWpGaD
Flunisolide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00257	0.0099	CbGpPWpGaD
Flunisolide—Erythema multiforme—Epirubicin—liver cancer	0.00254	0.00344	CcSEcCtD
Flunisolide—Rhinitis—Doxorubicin—liver cancer	0.0025	0.00337	CcSEcCtD
Flunisolide—Hypoaesthesia—Doxorubicin—liver cancer	0.00248	0.00335	CcSEcCtD
Flunisolide—Pharyngitis—Doxorubicin—liver cancer	0.00247	0.00334	CcSEcCtD
Flunisolide—Oedema peripheral—Doxorubicin—liver cancer	0.00245	0.00331	CcSEcCtD
Flunisolide—Chills—Epirubicin—liver cancer	0.00241	0.00326	CcSEcCtD
Flunisolide—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.0024	0.00926	CbGpPWpGaD
Flunisolide—Erythema multiforme—Doxorubicin—liver cancer	0.00235	0.00318	CcSEcCtD
Flunisolide—Malnutrition—Epirubicin—liver cancer	0.00234	0.00316	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptors—ESR1—liver cancer	0.00234	0.00902	CbGpPWpGaD
Flunisolide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—liver cancer	0.00234	0.00902	CbGpPWpGaD
Flunisolide—Dysgeusia—Epirubicin—liver cancer	0.00229	0.0031	CcSEcCtD
Flunisolide—Back pain—Epirubicin—liver cancer	0.00227	0.00306	CcSEcCtD
Flunisolide—Chills—Doxorubicin—liver cancer	0.00223	0.00302	CcSEcCtD
Flunisolide—NR3C1—Transcription factor regulation in adipogenesis—MAPK8—liver cancer	0.00222	0.00855	CbGpPWpGaD
Flunisolide—Vision blurred—Epirubicin—liver cancer	0.00221	0.00298	CcSEcCtD
Flunisolide—Ill-defined disorder—Epirubicin—liver cancer	0.00217	0.00293	CcSEcCtD
Flunisolide—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00217	0.00838	CbGpPWpGaD
Flunisolide—Malnutrition—Doxorubicin—liver cancer	0.00217	0.00293	CcSEcCtD
Flunisolide—Agitation—Epirubicin—liver cancer	0.00215	0.00291	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptors—PPARG—liver cancer	0.00213	0.00823	CbGpPWpGaD
Flunisolide—Dysgeusia—Doxorubicin—liver cancer	0.00212	0.00287	CcSEcCtD
Flunisolide—Malaise—Epirubicin—liver cancer	0.00211	0.00285	CcSEcCtD
Flunisolide—Vertigo—Epirubicin—liver cancer	0.0021	0.00284	CcSEcCtD
Flunisolide—Syncope—Epirubicin—liver cancer	0.0021	0.00284	CcSEcCtD
Flunisolide—Back pain—Doxorubicin—liver cancer	0.0021	0.00283	CcSEcCtD
Flunisolide—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00209	0.00806	CbGpPWpGaD
Flunisolide—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00208	0.00802	CbGpPWpGaD
Flunisolide—Palpitations—Epirubicin—liver cancer	0.00207	0.0028	CcSEcCtD
Flunisolide—NR3C1—Adipogenesis—AHR—liver cancer	0.00206	0.00795	CbGpPWpGaD
Flunisolide—Loss of consciousness—Epirubicin—liver cancer	0.00206	0.00278	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—F2—liver cancer	0.00206	0.00793	CbGpPWpGaD
Flunisolide—Cough—Epirubicin—liver cancer	0.00204	0.00276	CcSEcCtD
Flunisolide—Vision blurred—Doxorubicin—liver cancer	0.00204	0.00276	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—PPARA—liver cancer	0.00204	0.00787	CbGpPWpGaD
Flunisolide—Hypertension—Epirubicin—liver cancer	0.00202	0.00273	CcSEcCtD
Flunisolide—Ill-defined disorder—Doxorubicin—liver cancer	0.00201	0.00272	CcSEcCtD
Flunisolide—Chest pain—Epirubicin—liver cancer	0.00199	0.00269	CcSEcCtD
Flunisolide—Myalgia—Epirubicin—liver cancer	0.00199	0.00269	CcSEcCtD
Flunisolide—Agitation—Doxorubicin—liver cancer	0.00199	0.00269	CcSEcCtD
Flunisolide—Anxiety—Epirubicin—liver cancer	0.00199	0.00268	CcSEcCtD
Flunisolide—Discomfort—Epirubicin—liver cancer	0.00197	0.00266	CcSEcCtD
Flunisolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—SERPINE1—liver cancer	0.00196	0.00758	CbGpPWpGaD
Flunisolide—Malaise—Doxorubicin—liver cancer	0.00195	0.00264	CcSEcCtD
Flunisolide—Vertigo—Doxorubicin—liver cancer	0.00195	0.00263	CcSEcCtD
Flunisolide—Syncope—Doxorubicin—liver cancer	0.00194	0.00262	CcSEcCtD
Flunisolide—NR3C1—Circadian Clock—PPARA—liver cancer	0.00192	0.00741	CbGpPWpGaD
Flunisolide—Palpitations—Doxorubicin—liver cancer	0.00192	0.00259	CcSEcCtD
Flunisolide—Oedema—Epirubicin—liver cancer	0.00191	0.00258	CcSEcCtD
Flunisolide—Loss of consciousness—Doxorubicin—liver cancer	0.00191	0.00257	CcSEcCtD
Flunisolide—Infection—Epirubicin—liver cancer	0.0019	0.00256	CcSEcCtD
Flunisolide—Cough—Doxorubicin—liver cancer	0.00189	0.00255	CcSEcCtD
Flunisolide—Shock—Epirubicin—liver cancer	0.00188	0.00254	CcSEcCtD
Flunisolide—Hypertension—Doxorubicin—liver cancer	0.00187	0.00253	CcSEcCtD
Flunisolide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00187	0.0072	CbGpPWpGaD
Flunisolide—Tachycardia—Epirubicin—liver cancer	0.00187	0.00252	CcSEcCtD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—ESR1—liver cancer	0.00185	0.00713	CbGpPWpGaD
Flunisolide—Hyperhidrosis—Epirubicin—liver cancer	0.00185	0.0025	CcSEcCtD
Flunisolide—Myalgia—Doxorubicin—liver cancer	0.00185	0.00249	CcSEcCtD
Flunisolide—Chest pain—Doxorubicin—liver cancer	0.00185	0.00249	CcSEcCtD
Flunisolide—Anxiety—Doxorubicin—liver cancer	0.00184	0.00248	CcSEcCtD
Flunisolide—NR3C1—Regulation of Androgen receptor activity—MAPK14—liver cancer	0.00183	0.00705	CbGpPWpGaD
Flunisolide—Discomfort—Doxorubicin—liver cancer	0.00182	0.00246	CcSEcCtD
Flunisolide—NR3C1—AP-1 transcription factor network—CSF2—liver cancer	0.00181	0.00697	CbGpPWpGaD
Flunisolide—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.00179	0.00691	CbGpPWpGaD
Flunisolide—Oedema—Doxorubicin—liver cancer	0.00177	0.00239	CcSEcCtD
Flunisolide—Infection—Doxorubicin—liver cancer	0.00176	0.00237	CcSEcCtD
Flunisolide—NR3C1—Transcription factor regulation in adipogenesis—TNF—liver cancer	0.00176	0.00677	CbGpPWpGaD
Flunisolide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00174	0.00235	CcSEcCtD
Flunisolide—Shock—Doxorubicin—liver cancer	0.00174	0.00235	CcSEcCtD
Flunisolide—Insomnia—Epirubicin—liver cancer	0.00173	0.00233	CcSEcCtD
Flunisolide—Tachycardia—Doxorubicin—liver cancer	0.00173	0.00233	CcSEcCtD
Flunisolide—Hyperhidrosis—Doxorubicin—liver cancer	0.00171	0.00231	CcSEcCtD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—liver cancer	0.00171	0.00658	CbGpPWpGaD
Flunisolide—Dyspnoea—Epirubicin—liver cancer	0.0017	0.0023	CcSEcCtD
Flunisolide—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.0017	0.00655	CbGpPWpGaD
Flunisolide—NR3C1—Nuclear Receptor transcription pathway—PPARG—liver cancer	0.00169	0.00651	CbGpPWpGaD
Flunisolide—Dyspepsia—Epirubicin—liver cancer	0.00168	0.00227	CcSEcCtD
Flunisolide—Decreased appetite—Epirubicin—liver cancer	0.00166	0.00224	CcSEcCtD
Flunisolide—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00166	0.00639	CbGpPWpGaD
Flunisolide—Fatigue—Epirubicin—liver cancer	0.00165	0.00223	CcSEcCtD
Flunisolide—Constipation—Epirubicin—liver cancer	0.00164	0.00221	CcSEcCtD
Flunisolide—Pain—Epirubicin—liver cancer	0.00164	0.00221	CcSEcCtD
Flunisolide—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00163	0.00628	CbGpPWpGaD
Flunisolide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00161	0.00218	CcSEcCtD
Flunisolide—Insomnia—Doxorubicin—liver cancer	0.0016	0.00216	CcSEcCtD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—CSF2—liver cancer	0.00159	0.00614	CbGpPWpGaD
Flunisolide—Dyspnoea—Doxorubicin—liver cancer	0.00158	0.00213	CcSEcCtD
Flunisolide—Feeling abnormal—Epirubicin—liver cancer	0.00158	0.00213	CcSEcCtD
Flunisolide—Gastrointestinal pain—Epirubicin—liver cancer	0.00156	0.00211	CcSEcCtD
Flunisolide—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.00156	0.00602	CbGpPWpGaD
Flunisolide—Dyspepsia—Doxorubicin—liver cancer	0.00156	0.0021	CcSEcCtD
Flunisolide—Decreased appetite—Doxorubicin—liver cancer	0.00154	0.00208	CcSEcCtD
Flunisolide—Fatigue—Doxorubicin—liver cancer	0.00153	0.00206	CcSEcCtD
Flunisolide—Urticaria—Epirubicin—liver cancer	0.00152	0.00205	CcSEcCtD
Flunisolide—Pain—Doxorubicin—liver cancer	0.00151	0.00204	CcSEcCtD
Flunisolide—Constipation—Doxorubicin—liver cancer	0.00151	0.00204	CcSEcCtD
Flunisolide—Abdominal pain—Epirubicin—liver cancer	0.00151	0.00204	CcSEcCtD
Flunisolide—Body temperature increased—Epirubicin—liver cancer	0.00151	0.00204	CcSEcCtD
Flunisolide—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.0015	0.00579	CbGpPWpGaD
Flunisolide—Feeling abnormal—Doxorubicin—liver cancer	0.00146	0.00197	CcSEcCtD
Flunisolide—Gastrointestinal pain—Doxorubicin—liver cancer	0.00145	0.00195	CcSEcCtD
Flunisolide—NR3C1—AP-1 transcription factor network—ESR1—liver cancer	0.00144	0.00553	CbGpPWpGaD
Flunisolide—NR3C1—Circadian Clock—SERPINE1—liver cancer	0.00143	0.00552	CbGpPWpGaD
Flunisolide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00142	0.00548	CbGpPWpGaD
Flunisolide—NR3C1—Transcription factor regulation in adipogenesis—IL6—liver cancer	0.00142	0.00546	CbGpPWpGaD
Flunisolide—Hypersensitivity—Epirubicin—liver cancer	0.00141	0.0019	CcSEcCtD
Flunisolide—Urticaria—Doxorubicin—liver cancer	0.00141	0.0019	CcSEcCtD
Flunisolide—Abdominal pain—Doxorubicin—liver cancer	0.0014	0.00189	CcSEcCtD
Flunisolide—Body temperature increased—Doxorubicin—liver cancer	0.0014	0.00189	CcSEcCtD
Flunisolide—NR3C1—Endoderm Differentiation—APC—liver cancer	0.00139	0.00535	CbGpPWpGaD
Flunisolide—Asthenia—Epirubicin—liver cancer	0.00137	0.00185	CcSEcCtD
Flunisolide—Pruritus—Epirubicin—liver cancer	0.00135	0.00183	CcSEcCtD
Flunisolide—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00134	0.00518	CbGpPWpGaD
Flunisolide—Diarrhoea—Epirubicin—liver cancer	0.00131	0.00177	CcSEcCtD
Flunisolide—Hypersensitivity—Doxorubicin—liver cancer	0.0013	0.00176	CcSEcCtD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—MAPK14—liver cancer	0.00129	0.00497	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—liver cancer	0.00128	0.00492	CbGpPWpGaD
Flunisolide—Asthenia—Doxorubicin—liver cancer	0.00127	0.00171	CcSEcCtD
Flunisolide—Dizziness—Epirubicin—liver cancer	0.00126	0.00171	CcSEcCtD
Flunisolide—Pruritus—Doxorubicin—liver cancer	0.00125	0.00169	CcSEcCtD
Flunisolide—CYP3A4—Biological oxidations—UGDH—liver cancer	0.00122	0.00471	CbGpPWpGaD
Flunisolide—Vomiting—Epirubicin—liver cancer	0.00122	0.00164	CcSEcCtD
Flunisolide—Diarrhoea—Doxorubicin—liver cancer	0.00121	0.00163	CcSEcCtD
Flunisolide—Rash—Epirubicin—liver cancer	0.00121	0.00163	CcSEcCtD
Flunisolide—Dermatitis—Epirubicin—liver cancer	0.0012	0.00163	CcSEcCtD
Flunisolide—Headache—Epirubicin—liver cancer	0.0012	0.00162	CcSEcCtD
Flunisolide—Dizziness—Doxorubicin—liver cancer	0.00117	0.00158	CcSEcCtD
Flunisolide—NR3C1—Regulation of Androgen receptor activity—JUN—liver cancer	0.00116	0.00447	CbGpPWpGaD
Flunisolide—Nausea—Epirubicin—liver cancer	0.00114	0.00153	CcSEcCtD
Flunisolide—Vomiting—Doxorubicin—liver cancer	0.00112	0.00152	CcSEcCtD
Flunisolide—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.00112	0.00431	CbGpPWpGaD
Flunisolide—Rash—Doxorubicin—liver cancer	0.00112	0.00151	CcSEcCtD
Flunisolide—Dermatitis—Doxorubicin—liver cancer	0.00111	0.0015	CcSEcCtD
Flunisolide—Headache—Doxorubicin—liver cancer	0.00111	0.0015	CcSEcCtD
Flunisolide—NR3C1—AP-1 transcription factor network—CDKN2A—liver cancer	0.0011	0.00425	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of Androgen receptor activity—MAPK8—liver cancer	0.0011	0.00423	CbGpPWpGaD
Flunisolide—Nausea—Doxorubicin—liver cancer	0.00105	0.00142	CcSEcCtD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—liver cancer	0.00105	0.00405	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—NR1H4—liver cancer	0.000985	0.0038	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—CDKN1B—liver cancer	0.000976	0.00376	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—NR1I3—liver cancer	0.000968	0.00373	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—PPARA—liver cancer	0.000965	0.00372	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—IL2—liver cancer	0.000955	0.00368	CbGpPWpGaD
Flunisolide—NR3C1—Endoderm Differentiation—CTNNB1—liver cancer	0.000943	0.00364	CbGpPWpGaD
Flunisolide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000934	0.0036	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—CCND1—liver cancer	0.000931	0.00359	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—JUN—liver cancer	0.000929	0.00358	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—CTNNB1—liver cancer	0.000922	0.00355	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—MMP9—liver cancer	0.000904	0.00348	CbGpPWpGaD
Flunisolide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000903	0.00348	CbGpPWpGaD
Flunisolide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000891	0.00344	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—IL2—liver cancer	0.000841	0.00324	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—liver cancer	0.000826	0.00319	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—JUN—liver cancer	0.000818	0.00316	CbGpPWpGaD
Flunisolide—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000802	0.00309	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—liver cancer	0.000801	0.00309	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—PPARG—liver cancer	0.000798	0.00308	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—liver cancer	0.000793	0.00306	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—MAPK8—liver cancer	0.000774	0.00299	CbGpPWpGaD
Flunisolide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000772	0.00298	CbGpPWpGaD
Flunisolide—NR3C1—Endoderm Differentiation—TGFB1—liver cancer	0.000762	0.00294	CbGpPWpGaD
Flunisolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—liver cancer	0.000751	0.00289	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—MYC—liver cancer	0.000746	0.00288	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—TGFB1—liver cancer	0.000745	0.00287	CbGpPWpGaD
Flunisolide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000732	0.00282	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—SERPINE1—liver cancer	0.000719	0.00277	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000713	0.00275	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000701	0.00271	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000692	0.00267	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—HNF4A—liver cancer	0.000671	0.00259	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—liver cancer	0.000664	0.00256	CbGpPWpGaD
Flunisolide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000648	0.0025	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000642	0.00247	CbGpPWpGaD
Flunisolide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.00064	0.00247	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000633	0.00244	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000625	0.00241	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—TP53—liver cancer	0.000613	0.00236	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000603	0.00233	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000596	0.0023	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—EXOSC2—liver cancer	0.000596	0.0023	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000588	0.00227	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—CTNNB1—liver cancer	0.000562	0.00217	CbGpPWpGaD
Flunisolide—NR3C1—AP-1 transcription factor network—IL6—liver cancer	0.000561	0.00216	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—CDKN1A—liver cancer	0.000549	0.00212	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—TP53—liver cancer	0.00054	0.00208	CbGpPWpGaD
Flunisolide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000526	0.00203	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000504	0.00194	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.0005	0.00193	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—IL6—liver cancer	0.000494	0.00191	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—STAT3—liver cancer	0.00049	0.00189	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—JUN—liver cancer	0.000489	0.00189	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.000485	0.00187	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000477	0.00184	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—NR1H4—liver cancer	0.000474	0.00183	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—NR1I3—liver cancer	0.000466	0.0018	CbGpPWpGaD
Flunisolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—liver cancer	0.000461	0.00178	CbGpPWpGaD
Flunisolide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—liver cancer	0.000456	0.00176	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—TGFB1—liver cancer	0.000454	0.00175	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.000427	0.00165	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—TNF—liver cancer	0.000424	0.00163	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000389	0.0015	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000383	0.00148	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—TNF—liver cancer	0.000366	0.00141	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000357	0.00138	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—PPARA—liver cancer	0.000352	0.00136	CbGpPWpGaD
Flunisolide—NR3C1—Adipogenesis—IL6—liver cancer	0.000342	0.00132	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—HNF4A—liver cancer	0.000323	0.00125	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000321	0.00124	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—ESR1—liver cancer	0.000319	0.00123	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000316	0.00122	CbGpPWpGaD
Flunisolide—NR3C1—SIDS Susceptibility Pathways—IL6—liver cancer	0.000296	0.00114	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000295	0.00114	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—PPARG—liver cancer	0.000291	0.00112	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000291	0.00112	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—PSMD10—liver cancer	0.000282	0.00109	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—PSMA4—liver cancer	0.000282	0.00109	CbGpPWpGaD
Flunisolide—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000279	0.00108	CbGpPWpGaD
Flunisolide—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000275	0.00106	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—SERPINE1—liver cancer	0.000262	0.00101	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—UGDH—liver cancer	0.000209	0.000805	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—EPT1—liver cancer	0.000196	0.000757	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—H2AFX—liver cancer	0.000191	0.000736	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—TAT—liver cancer	0.000186	0.000718	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—PPARA—liver cancer	0.00017	0.000655	CbGpPWpGaD
Flunisolide—NR3C1—Generic Transcription Pathway—MYC—liver cancer	0.000166	0.000641	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—MAPK14—liver cancer	0.000157	0.000604	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—ESR1—liver cancer	0.000154	0.000593	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—PPARG—liver cancer	0.00014	0.000541	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—CPT1B—liver cancer	0.000127	0.000488	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GLUL—liver cancer	0.000127	0.000488	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—SERPINE1—liver cancer	0.000126	0.000487	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—NR1H4—liver cancer	0.000122	0.000471	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTA3—liver cancer	0.00012	0.000463	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTA4—liver cancer	0.00011	0.000423	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTA2—liver cancer	0.000107	0.000412	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTA1—liver cancer	0.000103	0.000398	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—NAT2—liver cancer	0.000102	0.000393	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—ALDOB—liver cancer	9.78e-05	0.000377	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—CRABP1—liver cancer	9.33e-05	0.00036	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—HPGDS—liver cancer	8.15e-05	0.000314	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—MYC—liver cancer	8e-05	0.000308	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PSMD10—liver cancer	7.27e-05	0.00028	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PSMA4—liver cancer	7.27e-05	0.00028	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GOT2—liver cancer	7.07e-05	0.000273	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—CYP2E1—liver cancer	6.65e-05	0.000256	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—CYCS—liver cancer	6.22e-05	0.00024	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GGT1—liver cancer	6.1e-05	0.000235	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GOT1—liver cancer	6.1e-05	0.000235	CbGpPWpGaD
Flunisolide—NR3C1—Gene Expression—AKT1—liver cancer	5.55e-05	0.000214	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTP1—liver cancer	5.48e-05	0.000211	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—HMOX1—liver cancer	5.41e-05	0.000209	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—GSTM1—liver cancer	5.04e-05	0.000194	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—CYP1A1—liver cancer	4.78e-05	0.000184	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—MTHFR—liver cancer	4.45e-05	0.000172	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PPARA—liver cancer	4.37e-05	0.000168	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PIK3CG—liver cancer	3.74e-05	0.000144	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PPARG—liver cancer	3.61e-05	0.000139	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PIK3CD—liver cancer	3.29e-05	0.000127	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—ALB—liver cancer	3.25e-05	0.000125	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PIK3CB—liver cancer	2.87e-05	0.000111	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—PIK3CA—liver cancer	1.75e-05	6.74e-05	CbGpPWpGaD
Flunisolide—CYP3A4—Metabolism—AKT1—liver cancer	1.43e-05	5.5e-05	CbGpPWpGaD
